welcome to oneFAPvoice- a positively charged Familial Adenomatous Polyposis community.
- join today!
Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt Announce Results from Pivotal Phase 3 Trial of CPP-1X/Sulindac in Patients With Familial Adenomatous Polyposis
Cancer Prevention Pharmaceuticals, Inc., a private biotech company developing novel therapeutics to prevent cancer and other diseases, and its partner Mallinckrodt Plc, a leading global specialty pharmaceutical company, today announced that CPP’s pivotal phase 3 clinical trial, CPP FAP-310, of the investigational drug CPP-1X/sulindac in patients with familial adenomatous polyposis (FAP), did not meet its primary endpoint. Specifically, the reduction of time to the first occurrence of an FAP-related event for the combination of CPP-1X (eflornithine) and sulindac (a nonsteroidal anti-inflammatory drug) did not reach statistical significance compared to the two control arms. CPP FAP-310 included only active comparator arms and was the largest and longest study ever conducted in patients with FAP.
“While we are disappointed that the CPP FAP-310 clinical trial did not achieve its primary endpoint, we are encouraged by the data that relate to important outcome measures,” said CPP CEO Jeff Jacob.
expertly curated content related to this topic
Prospective Randomized Study of Sulindac versus Calcium and Calciferol for Upper Gastrointestinal Polyps in Familial...Eighteen patients with familial adenomat...
Sulindac Sulfone Induced Regression of Rectal Polyps in Patients with Familial Adenomatous PolyposisSulindac sulfone (Exisulind), a metaboli...
Effects of Intervention with Sulindac and Inulin/vsl#3 on Mucosal and Luminal Factors in the Pouch of Patients with ...BACKGROUND/AIM: In order to define futu...
benjamin fryerTeam Leader, CMC, Cardiomyocyte Cell Man...
Fokko M. NagengastTeacher at Wageningen University, Divisi...
Multistage Vector Delivery of Sulindac and Silymarin for Prevention of Colon CancerFamilial adenomatous polyposis (FAP) is ...